Latest Peptidomimetic Stories
Researchers have developed a simple and versatile method for making artificial anti-cancer molecules that mimic the properties of one of the body's natural defense systems.
Researchers from the Hebrew University of Jerusalem and the Weizmann Institute of Science have developed a technique to cause apoptosis, or programmed cell death, that could lead to new approaches to treating cancer.
Scientists at the Dana-Farber/Children's Hospital Cancer Center have developed an anti-cancer peptide that overcomes the stubborn resistance to chemotherapy and radiation often encountered in certain blood cancers when the disease recurs following initial treatment.
MALVERN, Pa., May 24, 2011 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced that is has closed a $6 million investment with new investor Nextech Invest Ltd., a Zurich, Switzerland, based oncology focused venture capital fund.
Basic and translational research on cancer, and development of new cancer therapeutics, has focused on different aspects of cancer cellular function.
MALVERN, Pa., Jan. 5, 2011 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced that is has closed the $23 million second tranche of a Series C financing completed in October 2010.
ALBANY, Ore., Aug. 3 /PRNewswire-FirstCall/ -- Synthetech, Inc. (OTC Bulletin Board: NZYM) today announced it will issue first quarter fiscal 2011 financial results before the opening of the market on Friday, August 6, 2010.
ALBANY, Ore., June 28 /PRNewswire-FirstCall/ -- Synthetech, Inc. (OTC Bulletin Board: NZYM) today announced that it has engaged Brocair Partners, LLC to conduct a comprehensive review of strategic alternatives aimed at enhancing shareholder value.
- totally perplexed and mixed up.